

# ISO/TR 10993-22:2017-07 (E)

## Biological evaluation of medical devices - Part 22: Guidance on nanomaterials

---

Contents		Page
Foreword .....	v	
Introduction .....	vi	
1 Scope .....	1	
2 Normative references .....	2	
3 Terms and definitions .....	2	
4 General principles .....	5	
4.1 General considerations .....	5	
4.2 Biological evaluation of nanomaterials .....	6	
4.3 Categorization of nanomaterials .....	6	
4.4 Nanomaterial equivalence .....	8	
5 Characterization of nanomaterials .....	8	
5.1 General considerations .....	8	
5.2 Characterization parameters and methods .....	10	
5.3 Use of reference materials .....	14	
6 Sample preparation .....	15	
6.1 General considerations .....	15	
6.2 Special considerations for nanostructured materials .....	15	
6.3 Special considerations for nano-objects .....	15	
6.4 Identity, storage and stability of stock nanomaterials .....	17	
6.5 Description of chemical composition of stock and dosing dispersions .....	17	
6.6 Characterization of stock dispersions .....	18	
6.7 Characterization of dosing solutions prepared from stock dispersions .....	18	
6.8 Dose metrics .....	19	
6.9 Additional considerations .....	19	
6.9.1 Endotoxin .....	19	
6.9.2 Sterilization .....	20	
7 Release of nano-objects from medical devices .....	21	
7.1 General considerations .....	21	
7.2 Degradation products .....	22	
7.3 Release of nano-objects by wear .....	22	
7.4 In situ processing .....	22	
8 Toxicokinetics .....	22	
8.1 General considerations .....	22	
8.2 Factors influencing the toxicokinetics .....	23	
8.2.1 Physicochemical properties .....	23	
8.2.2 Biomolecular adsorption .....	24	
8.2.3 Exposure route .....	25	
8.2.4 Dose .....	25	
8.2.5 Species and gender .....	25	
8.2.6 Measurement techniques .....	26	
9 Toxicological evaluation .....	26	
9.1 General considerations .....	26	

<b>9.2</b>	<b>In vitro cytotoxicity testing .....</b>	<b>27</b>
9.2.1	General considerations .....	27
9.2.2	Consideration of nanomaterial interference with the assays .....	28
9.2.3	Consideration of relevant dose and dose metrics .....	28
9.2.4	Consideration of nano-object kinetics .....	28
<b>9.3</b>	<b>Genotoxicity, carcinogenicity and reproductive toxicity .....</b>	<b>29</b>
9.3.1	General considerations .....	29
9.3.2	In vitro genotoxicity tests .....	30
9.3.3	In vivo genotoxicity tests .....	31
9.3.4	Carcinogenicity .....	32
9.3.5	Reproductive toxicity .....	32
<b>9.4</b>	<b>Immunotoxicity, irritation and sensitization .....</b>	<b>33</b>
9.4.1	General considerations .....	33
9.4.2	Immunotoxicity .....	33
9.4.3	Sensitization .....	34
9.4.4	Irritation .....	35
<b>9.5</b>	<b>Haemocompatibility .....</b>	<b>36</b>
9.5.1	General considerations .....	36
9.5.2	Complement system activation .....	37
9.5.3	Specific considerations for haemocompatibility testing .....	37
<b>9.6</b>	<b>Systemic toxicity .....</b>	<b>37</b>
<b>9.7</b>	<b>Pyrogenicity .....</b>	<b>38</b>
<b>9.8</b>	<b>Implantation .....</b>	<b>39</b>
<b>10</b>	<b>Presentation of characterization and test results .....</b>	<b>39</b>
<b>11</b>	<b>Risk assessment .....</b>	<b>40</b>
11.1	General considerations .....	40
11.2	Exposure assessment .....	42
11.3	Biological hazard identification .....	43
11.4	Risk estimation .....	44
11.5	Risk evaluation .....	44
<b>12</b>	<b>Biological evaluation report .....</b>	<b>44</b>
<b>Bibliography .....</b>	<b>46</b>	